Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore presented to investors at the Pitt Street Research Life Sciences Conference in Sydney last month. During his presentation, Steve spoke to the Anatara story and the exciting year we have ahead with upcoming corporate milestones on both our human and animal health product opportunities.
Zoono Group Limited (ASX:ZNO) is pleased to announce that, following six months of trials across several animal health industry sectors, a group of leaders in the Chinese agribusiness/veterinarian and animal feed sector have agreed to jointly collaborate and form a new entity to act as Zoono's exclusive distributor for the animal health and agribusiness sector in China.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the Pitt Street Research Life Sciences Conference, held in Sydney, NSW.
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $847,325 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.
2019 was a productive year as we continued our aim of commercialising Progenza and Sygenus, our core regenerative medicine technology platforms. In particular, our focus has been on the lead platform, Progenza, which has shown positive results for treating osteoarthritis in its Phase 1 trials.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has placed the full shortfall of 9,437,872 shares under its recent Non-Renounceable Rights Issue. The shortfall was placed to a Japan-based institutional investor at an issue price of A$0.08 per share for a total of A$755,029.
Anatara's CEO Steve Lydeamore has been invited to present at the Pitt Street Research Life Sciences Conference on the 28th November in Sydney. Any investors interested in attending these presentations are invited to reach out.
